Literature DB >> 24028863

Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool.

Asikiya Walcourt1, Joseph Kurantsin-Mills, John Kwagyan, Babafemi B Adenuga, Danuta S Kalinowski, David B Lovejoy, Darius J R Lane, Des R Richardson.   

Abstract

Iron chelators inhibit the growth of the malaria parasite, Plasmodium falciparum, in culture and in animal and human studies. We previously reported the anti-plasmodial activity of the chelators, 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (311), 2-hydroxy-1-naphthylaldehyde 4-methyl-3-thiosemicarbazone (N4mT), and 2-hydroxy-1-naphthylaldehyde 4-phenyl-3-thiosemicarbazone (N4pT). In fact, these ligands showed greater growth inhibition of chloroquine-sensitive (3D7) and chloroquine-resistant (7G8) strains of P. falciparum in culture compared to desferrioxamine (DFO). The present study examined the effects of 311, N4mT and N4pT on erythrocyte membrane integrity and asexual parasite development. While the characteristic biconcave disk shape of the erythrocytes was unaffected, the chelators caused very slight hemolysis at IC50 values that inhibited parasite growth. The chelators 311, N4mT and N4pT affected all stages of the intra-erythrocytic development cycle (IDC) of P. falciparum in culture. However, while these ligands primarily affected the ring-stage, DFO inhibited primarily trophozoite and schizont-stages. Ring, trophozoite and schizont-stages of the IDC were inhibited by significantly lower concentrations of 311, N4mT, and N4pT (IC50=4.45±1.70, 10.30±4.40, and 3.64±2.00μM, respectively) than DFO (IC50=23.43±3.40μM). Complexation of 311, N4mT and N4pT with iron reduced their anti-plasmodial activity. Estimation of the intracellular labile iron pool (LIP) in erythrocytes showed that the chelation efficacy of 311, N4mT and N4pT corresponded to their anti-plasmodial activities, suggesting that the LIP may be a potential source of non-heme iron for parasite metabolism within the erythrocyte. This study has implications for malaria chemotherapy that specifically disrupts parasite iron utilization.
© 2013.

Entities:  

Keywords:  Aroylhydrazone; Erythrocytes; Iron chelator; Plasmodium falciparum; Thiosemicarbazone

Mesh:

Substances:

Year:  2013        PMID: 24028863      PMCID: PMC3838870          DOI: 10.1016/j.jinorgbio.2013.08.007

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  51 in total

1.  In vitro potentiation of antibiotic activities by a catecholate iron chelator against chloroquine-resistant Plasmodium falciparum.

Authors:  Bruno Pradines; Florence Ramiandrasoa; Jean Marc Rolain; Christophe Rogier; Joel Mosnier; William Daries; Thierry Fusai; Gerhard Kunesch; Jacques Le Bras; Daniel Parzy
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  A voltage-dependent channel involved in nutrient uptake by red blood cells infected with the malaria parasite.

Authors:  S A Desai; S M Bezrukov; J Zimmerberg
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

3.  Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.

Authors:  Patricia Quach; Elaine Gutierrez; Maram Talal Basha; Danuta S Kalinowski; Philip C Sharpe; David B Lovejoy; Paul V Bernhardt; Patric J Jansson; Des R Richardson
Journal:  Mol Pharmacol       Date:  2012-04-16       Impact factor: 4.436

4.  In vitro Plasmodium falciparum drug sensitivity assay: inhibition of parasite growth by incorporation of stomatocytogenic amphiphiles into the erythrocyte membrane.

Authors:  Hanne L Ziegler; Dan Staerk; Jette Christensen; Lars Hviid; Henry Hägerstrand; Jerzy W Jaroszewski
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 5.  Malaria parasite development in the mosquito and infection of the mammalian host.

Authors:  Ahmed S I Aly; Ashley M Vaughan; Stefan H I Kappe
Journal:  Annu Rev Microbiol       Date:  2009       Impact factor: 15.500

6.  Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells.

Authors:  David B Lovejoy; Des R Richardson
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

7.  Each member of the poly-r(C)-binding protein 1 (PCBP) family exhibits iron chaperone activity toward ferritin.

Authors:  Sebastien Leidgens; Kimberly Z Bullough; Haifeng Shi; Fengmin Li; Minoo Shakoury-Elizeh; Toshiki Yabe; Poorna Subramanian; Emory Hsu; Navin Natarajan; Anjali Nandal; Timothy L Stemmler; Caroline C Philpott
Journal:  J Biol Chem       Date:  2013-05-02       Impact factor: 5.157

8.  Direct tests of enzymatic heme degradation by the malaria parasite Plasmodium falciparum.

Authors:  Paul A Sigala; Jan R Crowley; Samantha Hsieh; Jeffrey P Henderson; Daniel E Goldberg
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

9.  Surface area loss and increased sphericity account for the splenic entrapment of subpopulations of Plasmodium falciparum ring-infected erythrocytes.

Authors:  Innocent Safeukui; Pierre A Buffet; Sylvie Perrot; Alain Sauvanet; Beatrice Aussilhou; Safi Dokmak; Anne Couvelard; Dominique Cazals Hatem; Narla Mohandas; Peter H David; Odile Mercereau-Puijalon; Geneviève Milon
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

10.  The homeostasis of Plasmodium falciparum-infected red blood cells.

Authors:  Jakob M A Mauritz; Alessandro Esposito; Hagai Ginsburg; Clemens F Kaminski; Teresa Tiffert; Virgilio L Lew
Journal:  PLoS Comput Biol       Date:  2009-04-03       Impact factor: 4.475

View more
  1 in total

1.  An investigation on 3-acetyl-7-methoxy-coumarin Schiff bases and their Ru(ii) metallates with potent antiproliferative activity and enhanced LDH and NO release.

Authors:  G Kalaiarasi; S Rex Jeya Rajkumar; S Dharani; J G Małecki; R Prabhakaran
Journal:  RSC Adv       Date:  2018-01-04       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.